Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
Do you avoid the use of beta blockers when treating hyperthyroidism in patients with well controlled asthma or COPD?
Related Questions
What empiric dose change, if any, do you make for patients already taking liquid or softgel levothyroxine preconception upon confirmation of a positive pregnancy test?
Do you recommend low dose RAI ablation for low risk papillary thyroid cancer with lymphatic invasion alone (no angio-invasion or known nodal involvement)?
Do you have a preference between RAI therapy and antithyroid medication for patients with Graves' hyperthyroidism and moderate-to-severe Graves' orbitopathy who are on glucocorticoid treatment?
How far in advance of a nuclear medicine thyroid update and scan should thionamides be discontinued and does this duration vary based on radio-isotope used (i.e. technetium versus RAI 123)?
For patients with low risk, differentiated thyroid cancer, how do you navigate the decision between less aggressive treatments, such as lobectomy alone without radioactive iodine, and more aggressive strategies?
When, if ever, is it appropriate to switch from generic levothyroxine to brand name Synthroid?
Would you ever recommend radiofrequency ablation over surgery or radioiodine for a patient with an autonomously functioning thyroid nodule?
What TSH cut off do you use to determine the need for levothyroxine supplementation in a pregnant patient with positive TPO antibodies?
Is there a role for increasing dietary vitamin E in patients at risk for developing autoimmune thyroiditis?
For patients on T4/T3 combination therapy for management of hypothyroidism is there an indication for monitoring T3 levels and if so, what is the appropriate timing (trough versus peak) given the pharmacokinetics of liothyronine?
